Biotechnology
REGENXBIO is a gene therapy company founded in 2009 that pioneers treatments for patients facing serious rare and retinal diseases. The company is advancing a pipeline of gene therapies designed to improve patient outcomes, with a focus on commercializing innovative medicines. Their rare disease portfolio includes programs such as RGX-202, which represents a key component of their commercial strategy. REGENXBIO's mission is driven by purpose and urgency, with a talented team committed to developing potentially transformative gene therapies that make a meaningful difference for patients and their families.
Industry
Biotechnology
Founded
2009
Beta · Sourced from candidate reports
Be the first to share your experience with REGENXBIO.
Your reply helps other candidates know what to expect.
